Growth Attenuation Therapy

Area of Science:

• Bioethics
• Pediatric Healthcare
• Medical Ethics

Background:

• The "Ashley treatment," involving growth attenuation therapy (GAT), is ethically controversial and increasingly requested for children with profound cognitive impairment (PCI).
• Existing literature inadequately represents the perspectives of parents of children with PCI regarding GAT.
• There is a clinical and ethical need for guidance on responding to GAT requests.

Purpose of the Study:

• To analyze and represent the underrepresented views of parents concerning growth attenuation therapy (GAT) for children with profound cognitive impairment (PCI).
• To illuminate how parents characterize benefits and harms associated with GAT.
• To explore parental responsibilities as surrogate decision-makers in GAT cases.

Main Methods:

• Qualitative analysis of published accounts from parents who support or oppose GAT for their children with PCI.
• Examination of parental perspectives on the benefits, harms, and ethical considerations of GAT.
• Synthesis of parental views to inform clinical and ethical decision-making.

Main Results:

• Parental accounts reveal diverse characterizations of benefits and harms related to GAT.
• Parental decision-making for GAT involves complex considerations of child welfare and surrogate responsibilities.
• Significant disparities exist in how parents perceive the ethical implications of GAT.

Conclusions:

• Understanding parental perspectives is crucial for ethical decision-making regarding GAT for children with PCI.
• The analysis contributes to addressing the gap in literature concerning parental views on GAT.
• Findings may inform broader healthcare decision-making processes for children with profound cognitive impairment.